Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sulphonylurea · 1 trial · 1 indication
Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value.
| Arm | Type | Description |
|---|---|---|
| Saxagliptin | EXPERIMENTAL | - |
| Glipizide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Metformin | DRUG | open-label metformin |
| Sulphonylurea | DRUG | Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks) |
| Saxagliptin | DRUG | Saxagliptin 5 mg tablets |
Inclusion Criteria: * Diagnosed with type 2 diabetes, * Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1, * HbA1c \>6.5% and ≤10.0% Exclusion Criteria: * Type 1 diabetes, * history of diabetic ketoacidosis or hyperosmolar non-ketoni...
Top 20 of 31 competitors
Sulphonylurea is an investigational small molecule being studied for the treatment of Type 2 Diabetes. It is currently in Phase 3 clinical development, though no approval has been granted. The drug is being evaluated as an add-on therapy to metformin in a completed clinical trial.
Sulphonylurea targets the sulfonylurea receptor, a class of drugs that stimulate insulin release from pancreatic beta cells. This mechanism helps lower blood glucose levels in patients with Type 2 Diabetes. The drug is being developed as a small molecule therapy.
Sulphonylurea is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes.
Sulphonylurea is in Phase 3 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 3 trial has been completed, but the drug remains under investigation for the treatment of Type 2 Diabetes.
Sulphonylurea has one completed Phase 3 clinical trial with the identifier NCT00575588. This trial was a 52-week add-on to metformin study comparing saxagliptin and sulphonylurea, with a 52-week extension period. The trial enrolled 891 participants across multiple countries.
No, Sulphonylurea is not the same as Saxagliptin. In the clinical trial NCT00575588, saxagliptin and sulphonylurea were compared as separate add-on treatments to metformin in patients with Type 2 Diabetes. Sulphonylurea is a distinct drug candidate being developed by AstraZeneca.